Ken Griffin Novavax Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$10.71 - $17.11 $842,877 - $1.35 Million	78,700 Added 7.92%	1,073,000 $13.6 Million
Q2 2024 Aug 14, 2024	BUY	$3.89 - $20.97 $1.81 Million - $9.75 Million	464,900 Added 87.82%	994,300 $12.6 Million
Q1 2024 May 15, 2024	SELL	$3.76 - $6.02 $1.86 Million - $2.97 Million	-493,800 Reduced 48.26%	529,400 $2.53 Million
Q4 2023 Feb 14, 2024	SELL	$4.8 - $7.67 $1.18 Million - $1.88 Million	-245,500 Reduced 19.35%	1,023,200 $4.91 Million
Q3 2023 Nov 14, 2023	BUY	$6.81 - $9.74 $1.28 Million - $1.83 Million	187,800 Added 17.37%	1,268,700 $9.19 Million
Q2 2023 Aug 14, 2023	SELL	$6.67 - $9.52 $6.23 Million - $8.89 Million	-934,300 Reduced 46.36%	1,080,900 $8.03 Million
Q1 2023 May 15, 2023	BUY	$5.76 - $12.48 $440,064 - $953,472	76,400 Added 3.94%	2,015,200 $14 Million
Q4 2022 Feb 14, 2023	BUY	$8.86 - $25.04 $6.11 Million - $17.3 Million	689,700 Added 55.22%	1,938,800 $19.9 Million
Q3 2022 Nov 14, 2022	SELL	$18.2 - $76.12 $5.17 Million - $21.6 Million	-284,200 Reduced 18.54%	1,249,100 $22.7 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.